Genetic IL-6 receptor blockade links to lower sepsis risk
Mendelian randomisation treating IL6R variants as a natural experiment for receptor blockade found lower odds of sepsis (OR 0.80) and critical-care sepsis (OR 0.48) in UK Biobank, with a similar-sized protective association for severe COVID-19.
Source
Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study
Study at a glance
- Design
- Mendelian randomisation — IL6R genetic instruments as proxies for lifelong IL-6 receptor blockade; UK Biobank primary
- N
- N=486484 · UK Biobank ≈486,484 adults including 11,643 sepsis cases; secondary FinnGen and COVID-19 HGI
- Population
- UK Biobank adults (with secondary European/COVID genetics cohorts)
- Outcome
- Odds of sepsis (and severe sepsis / severe COVID-19 phenotypes)
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Authors used Mendelian randomisation with IL6R genetic instruments as proxies for lifelong IL-6 receptor blockade (the pharmacology target of drugs such as tocilizumab). Primary analyses used UK Biobank (~486k adults, 11,643 with sepsis), with secondary cohorts including FinnGen and COVID-19 Host Genetics Initiative data.
What they found
Genetically proxied IL6R blockade associated with lower odds of sepsis (OR 0.80, 95% CI 0.66–0.96) and stronger associations for more severe phenotypes such as critical-care admission with sepsis (OR 0.48). A protective association of similar magnitude was confirmed for severe COVID-19 (OR 0.69), where IL-6 blockade is already recommended in critical illness.
The limits
What it doesn't show
MR estimates lifelong genetic exposure, not a same-day ICU tocilizumab RCT for bacterial sepsis. Some secondary critical-care survival intervals are wide and compatible with no effect. Results support a therapeutic hypothesis and trial priority — they do not license off-label IL6RA use for every sepsis case.
Key terms
- Mendelian randomisation (MR)
- Uses genetic variants as instrumental variables to estimate causal effects of a pathway (here IL6R blockade).
- IL6R / IL6RA
- Interleukin-6 receptor and receptor-antagonist drugs (e.g., tocilizumab, sarilumab).
- UK Biobank sepsis outcome
- Primary binary sepsis phenotype in ~486k adults including 11,643 sepsis cases.
- Critical-care sepsis
- More severe phenotype (ICU admission with sepsis) showing a stronger protective OR in these analyses.
- Natural experiment
- Authors’ framing of IL6R variants as lifelong proxies for receptor blockade.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
What does Mendelian randomisation contribute here?
Common questions
What method estimates the IL6R effect?
Mendelian randomisation using IL6R variants as instruments for receptor blockade.
What was the primary sepsis OR?
OR 0.80 (95% CI 0.66–0.96) for sepsis in UK Biobank per genetically proxied IL6R blockade.
Did severity matter?
Yes — associations strengthened for critical-care sepsis phenotypes (e.g., OR 0.48 for critical-care admission with sepsis).
How does this relate to COVID-19?
A similar protective OR (~0.69) for severe COVID-19 matches a setting where IL-6 blockade is already recommended.
Is this the same as giving tocilizumab in bacterial sepsis today?
No — genetic proxies support a causal hypothesis; bedside use still needs sepsis-specific trial evidence.
More on Critical care